NASDAQ:CBAY CymaBay Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CymaBay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.77 -0.18 (-6.10%) (As of 07/1/2022 05:43 PM ET) Add Compare Share Today's Range$2.77▼$2.9850-Day Range$1.72▼$2.9552-Week Range$1.67▼$4.74Volume387,294 shsAverage Volume607,840 shsMarket Capitalization$234.56 millionP/E RatioN/ADividend YieldN/APrice Target$10.80 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability CymaBay Therapeutics Stock Forecast (MarketRank)Analyst RatingBuy3.25 Rating ScoreUpside/Downside289.9% Upside$10.80 Price TargetShort InterestBearish5.65% of Float Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.62Based on 3 Articles This WeekInsider TradingAcquiring Shares$100.04 K Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.23) to ($1.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.33 out of 5 starsMedical Sector226th out of 1,429 stocksPharmaceutical Preparations Industry88th out of 682 stocks 3.6 Analyst's Opinion Consensus RatingCymaBay Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.80, CymaBay Therapeutics has a forecasted upside of 289.9% from its current price of $2.77.Amount of Analyst CoverageCymaBay Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.65% of the float of CymaBay Therapeutics has been sold short.Short Interest Ratio / Days to CoverCymaBay Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in CymaBay Therapeutics has recently increased by 17.54%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCymaBay Therapeutics does not currently pay a dividend.Dividend GrowthCymaBay Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCymaBay Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for CymaBay Therapeutics is -0.88. Previous Next 2.6 News and Social Media Coverage News SentimentCymaBay Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CymaBay Therapeutics this week, compared to 1 article on an average week.Search Interest15 people have searched for CBAY on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added CymaBay Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CymaBay Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,037.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of CymaBay Therapeutics is held by insiders.Percentage Held by Institutions78.34% of the stock of CymaBay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CymaBay Therapeutics are expected to decrease in the coming year, from ($1.23) to ($1.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CymaBay Therapeutics is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CymaBay Therapeutics is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCymaBay Therapeutics has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CBAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About CymaBay Therapeutics (NASDAQ:CBAY)CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.Read More CBAY Stock News HeadlinesJune 27, 2022 | seekingalpha.comCymaBay: Long-Term Potential Based On Prior PBC Trial ResultsJune 27, 2022 | americanbankingnews.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Receives $10.80 Consensus Price Target from BrokeragesJune 22, 2022 | marketwatch.comCymaBay Therapeutics Shares Rise 7% After Positive Data for Seladelpar TrialJune 22, 2022 | finance.yahoo.comCymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2022June 9, 2022 | finance.yahoo.comTrade Alert: The President Of CymaBay Therapeutics, Inc. (NASDAQ:CBAY), Sujal Shah, Has Just Spent US$100k Buying 43% More SharesJune 9, 2022 | americanbankingnews.comCymaBay Therapeutics, Inc. Forecasted to Earn FY2023 Earnings of ($1.45) Per Share (NASDAQ:CBAY)June 8, 2022 | finance.yahoo.comCymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2022May 23, 2022 | seekingalpha.comCymaBay announces result from two-year study of primary biliary cholangitis therapyMay 23, 2022 | finance.yahoo.comCymaBay's New Seladelpar Two-Year Data Shows Improved Transplant-Free SurvivalMay 23, 2022 | finance.yahoo.comCymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free SurvivalMay 16, 2022 | seekingalpha.comCymaBay price target lowered at H.C. Wainwright on enrollment delay for key studyMay 13, 2022 | benzinga.comCymaBay Therapeutics: Q1 Earnings InsightsMay 13, 2022 | seekingalpha.comCymaBay Therapeutics GAAP EPS of -$0.32 misses by $0.01See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBAY CUSIPN/A CIK1042074 Webwww.cymabay.com Phone(510) 293-8800Fax510-293-9090Employees59Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today7/01/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$10.80 High Stock Price Forecast$14.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+289.9%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.330010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-90 million Net MarginsN/A Pretax MarginN/A Return on Equity-92.26% Return on Assets-62.35% Debt Debt-to-Equity Ratio0.73 Current Ratio13.68 Quick Ratio13.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.93 per share Price / Book1.44Miscellaneous Outstanding Shares84,678,000Free Float80,021,000Market Cap$234.56 million OptionableOptionable Beta1.09 CymaBay Therapeutics Frequently Asked Questions Should I buy or sell CymaBay Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CymaBay Therapeutics stock. View analyst ratings for CymaBay Therapeutics or view top-rated stocks. What is CymaBay Therapeutics' stock price forecast for 2022? 4 brokers have issued 12 month price targets for CymaBay Therapeutics' stock. Their CBAY stock forecasts range from $8.00 to $14.00. On average, they predict CymaBay Therapeutics' stock price to reach $10.80 in the next year. This suggests a possible upside of 289.9% from the stock's current price. View analysts' price targets for CymaBay Therapeutics or view top-rated stocks among Wall Street analysts. How has CymaBay Therapeutics' stock price performed in 2022? CymaBay Therapeutics' stock was trading at $3.38 at the beginning of the year. Since then, CBAY shares have decreased by 18.0% and is now trading at $2.77. View the best growth stocks for 2022 here. When is CymaBay Therapeutics' next earnings date? CymaBay Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for CymaBay Therapeutics. How were CymaBay Therapeutics' earnings last quarter? CymaBay Therapeutics, Inc. (NASDAQ:CBAY) issued its quarterly earnings data on Thursday, May, 12th. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.01. During the same quarter last year, the firm earned ($0.25) earnings per share. View CymaBay Therapeutics' earnings history. Who are CymaBay Therapeutics' key executives? CymaBay Therapeutics' management team includes the following people: Mr. Sujal A. Shah, Pres, CEO & Director (Age 49, Pay $873.87k)Dr. Dennis D. Kim M.B.A., M.D., MBA, Chief Medical Officer (Age 52, Pay $406.11k)Mr. Lewis J. Stuart B.A., BA, M.B.A., MBA, Chief Commercial Officer (Age 63, Pay $378.79k)Mr. Daniel Menold, VP of Fin. (Age 52)Dr. Charles A. McWherter Ph.D., Sr. VP & Chief Scientific Officer (Age 67)Mr. Paul T. Quinlan, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 59)Mr. Ken Boehm, Sr. VP of HRMr. Patrick J. O'Mara, Sr. VP of Bus. Devel. (Age 61)Dr. Robert L. Martin, Sr. VP of Manufacturing & Nonclinical Devel. (Age 60)Ms. Klara A. Dickinson-Eason, Chief Regulatory & Quality Assurance Officer (Age 54) Who are some of CymaBay Therapeutics' key competitors? Some companies that are related to CymaBay Therapeutics include Aclaris Therapeutics (ACRS), Belite Bio (BLTE), SIGA Technologies (SIGA), Veru (VERU), uniQure (QURE), Deciphera Pharmaceuticals (DCPH), Morphic (MORF), ADVANZ PHARMA (CXRXF), Phibro Animal Health (PAHC), Design Therapeutics (DSGN), IGM Biosciences (IGMS), Nuvation Bio (NUVB), CinCor Pharma (CINC), Avidity Biosciences (RNA) and Verve Therapeutics (VERV). View all of CBAY's competitors. What other stocks do shareholders of CymaBay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX). What is CymaBay Therapeutics' stock symbol? CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY." How do I buy shares of CymaBay Therapeutics? Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CymaBay Therapeutics' stock price today? One share of CBAY stock can currently be purchased for approximately $2.77. How much money does CymaBay Therapeutics make? CymaBay Therapeutics (NASDAQ:CBAY) has a market capitalization of $234.56 million. The biopharmaceutical company earns $-90 million in net income (profit) each year or ($1.330010) on an earnings per share basis. How many employees does CymaBay Therapeutics have? CymaBay Therapeutics employs 59 workers across the globe. How can I contact CymaBay Therapeutics? CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The official website for CymaBay Therapeutics is www.cymabay.com. The biopharmaceutical company can be reached via phone at (510) 293-8800, via email at [email protected], or via fax at 510-293-9090. This page (NASDAQ:CBAY) was last updated on 7/1/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
